Compare Stocks: LNAI, MDXH, GOSS, and BCTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$4.03 +6.9%	$3.47	$2.60 ▼ $14.68	$35.06M	1.14	353,770 shs	277,772 shs
GOSS Gossamer Bio	$0.17 -15.0%	$0.17	$0.11 ▼ $3.87	$40.81M	2.04	18.98 million shs	29.05 million shs
LNAI Lunai Bioworks	$2.40 +9.1%	$2.71	$1.21 ▼ $21.20	$10.87M	0.41	1.41 million shs	69,836 shs
MDXH MDxHealth	$0.76 -4.1%	$0.50	$0.40 ▼ $5.33	$37.43M	1.42	2.56 million shs	190,782 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	+8.96%	+6.80%	+5.31%	+3.86%	-45.98%
GOSS Gossamer Bio	+16.86%	+42.91%	+50.37%	-6.15%	-91.33%
LNAI Lunai Bioworks	+3.29%	+1.85%	-5.58%	-16.03%	+219,999,900.00%
MDXH MDxHealth	+6.41%	+5.01%	+92.39%	+5.17%	-77.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$4.03 +6.9%	$3.47	$2.60 ▼ $14.68	$35.06M	1.14	353,770 shs	277,772 shs
GOSS Gossamer Bio	$0.17 -15.0%	$0.17	$0.11 ▼ $3.87	$40.81M	2.04	18.98 million shs	29.05 million shs
LNAI Lunai Bioworks	$2.40 +9.1%	$2.71	$1.21 ▼ $21.20	$10.87M	0.41	1.41 million shs	69,836 shs
MDXH MDxHealth	$0.76 -4.1%	$0.50	$0.40 ▼ $5.33	$37.43M	1.42	2.56 million shs	190,782 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	+8.96%	+6.80%	+5.31%	+3.86%	-45.98%
GOSS Gossamer Bio	+16.86%	+42.91%	+50.37%	-6.15%	-91.33%
LNAI Lunai Bioworks	+3.29%	+1.85%	-5.58%	-16.03%	+219,999,900.00%
MDXH MDxHealth	+6.41%	+5.01%	+92.39%	+5.17%	-77.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX Briacell Therap	1.00	Sell	N/A	N/A
GOSS Gossamer Bio	2.22	Hold	$3.20	1,740.14% Upside
LNAI Lunai Bioworks	1.00	Sell	N/A	N/A
MDXH MDxHealth	2.40	Hold	$2.17	186.56% Upside

Current Analyst Ratings Breakdown

Latest LNAI, MDXH, GOSS, and BCTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	BCTX Briacell Therap	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	LNAI Lunai Bioworks	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/25/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00 ➝ $2.00
5/26/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$9.20 per share	N/A
GOSS Gossamer Bio	$48.47M	0.84	N/A	N/A	($0.40) per share	-0.43
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	($9.92) per share	N/A
MDXH MDxHealth	$107.88M	0.35	N/A	N/A	($0.61) per share	-1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX Briacell Therap	-$26.31M	-$7.92	N/A	N/A	N/A	N/A	-153.53%	-129.26%	N/A
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
LNAI Lunai Bioworks	-$178.01M	-$0.40	N/A	N/A	N/A	N/A	-1,243.45%	-1,617.76%	N/A
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A

Latest LNAI, MDXH, GOSS, and BCTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
6/9/2026	Q3 2026	BCTX Briacell Therap	N/A	-$0.99	N/A	-$0.99	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
LNAI Lunai Bioworks	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX Briacell Therap	N/A	7.07	7.07
GOSS Gossamer Bio	N/A	0.53	0.53
LNAI Lunai Bioworks	N/A	0.19	0.19
MDXH MDxHealth	N/A	1.15	0.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX Briacell Therap	15.42%
GOSS Gossamer Bio	81.23%
LNAI Lunai Bioworks	71.41%
MDXH MDxHealth	N/A

Insider Ownership

Company	Insider Ownership
BCTX Briacell Therap	0.74%
GOSS Gossamer Bio	3.74%
LNAI Lunai Bioworks	0.50%
MDXH MDxHealth	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX Briacell Therap	8	8.70 million	8.64 million	No Data
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
LNAI Lunai Bioworks	20	4.53 million	4.51 million	N/A
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable

LNAI, MDXH, GOSS, and BCTX Headlines

Recent News About These Companies

BTIG Research Issues Pessimistic Forecast for MDxHealth (NASDAQ:MDXH) Stock Price

August 23 at 1:48 AM | americanbankingnews.com

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

August 21, 2026 | fool.com

MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of "Hold" by Brokerages

August 20, 2026 | americanbankingnews.com

Top Penny Stocks To Watch Now - August 16th

August 19, 2026 | americanbankingnews.com

3 Top Penny Stocks to Watch Today, 8/18/26

August 18, 2026 | tipranks.com

Penny Stocks Worth Watching - August 15th

August 18, 2026 | americanbankingnews.com

MDxHealth Soars to Record-Breaking Quarter with 14% Sequential Revenue Increase

August 17, 2026 | news.themarketisopen.comN

MDxHealth S.A. Q2 2026 Earnings Call Summary

August 15, 2026 | finance.yahoo.com

MDxHealth (NASDAQ:MDXH) Stock Rating Upgraded by Wall Street Zen

August 15, 2026 | americanbankingnews.com

MDxHealth says well-positioned to 'return to positive EBITDA'

August 14, 2026 | msn.com

MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2026 | zacks.com

MDxHealth Raises $20 Million in Direct Share Offering and Amends Articles After Capital Increase

August 13, 2026 | tipranks.com

Mdxhealth Reports Second Quarter 2026 Financial Results

August 13, 2026 | globenewswire.com

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

July 30, 2026 | globenewswire.com

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed ...

July 24, 2026 | enidnews.comE

Mdxhealth SA receives Nasdaq non-compliance notice

July 24, 2026 | msn.com

mdxhealth Receives Nasdaq Notice of Minimum Market Value Deficiency

July 24, 2026 | quiverquant.comQ

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

July 24, 2026 | globenewswire.com

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

July 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, MDXH, GOSS, and BCTX Company Descriptions

Briacell Therap NASDAQ:BCTX

$4.03 +0.26 (+6.90%)

As of 04:00 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Gossamer Bio NASDAQ:GOSS

$0.17 -0.03 (-14.96%)

As of 04:00 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Lunai Bioworks NASDAQ:LNAI

$2.40 +0.20 (+9.09%)

As of 04:00 PM Eastern

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

MDxHealth NASDAQ:MDXH

$0.76 -0.03 (-4.15%)

As of 04:00 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LNAI, MDXH, GOSS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LNAI, MDXH, GOSS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LNAI, MDXH, GOSS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, MDXH, GOSS, and BCTX Company Descriptions

Briacell Therap NASDAQ:BCTX

Gossamer Bio NASDAQ:GOSS

Lunai Bioworks NASDAQ:LNAI

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LNAI, MDXH, GOSS, and BCTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LNAI, MDXH, GOSS, and BCTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LNAI, MDXH, GOSS, and BCTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI, MDXH, GOSS, and BCTX Company Descriptions

Briacell Therap NASDAQ:BCTX

Gossamer Bio NASDAQ:GOSS

Lunai Bioworks NASDAQ:LNAI

MDxHealth NASDAQ:MDXH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools